Skip to main content
Premium Trial:

Request an Annual Quote

OIVD's Steven Gutman Leaving FDA for Academia

NEW YORK (GenomeWeb News) - Steven Gutman, director of the Office of In Vitro Diagnostic Device Safety and Evaluation, will leave the US Food and Drug Administration by the end of the year for a post in academia, GenomeWeb Daily News sister publication Pharmacogenomics Reporter reported today.
 
“I made the very difficult decision that it was time for a change,” Gutman told PGx Reporter this week.
 
Gutman said he plans to join the University of Central Florida in January, where he will be a professor of pathology and part of the founding faculty at the university’s new medical school.
 
“I will miss the people, the mission, and the fire of OIVD,” Gutman said. “It has been a lovely ride. I do hope to remain involved in personalized health care, both scientific and policy.”
 
The FDA has not yet announced who will replace Gutman.
 
In addition to his teaching post at UCF, Gutman said he also hopes to spend time writing and consulting.
 
Gutman, who has been at the agency for nearly 17 years, has been the top man at OIVD since November 2002, when the division was formed to consolidate all regulatory activities for in vitro diagnostics.
 

 
A more comprehensive version of this article, including more coverage of Gutman's tenure at FDA, appears in this week's issue of Pharmacogenomics Reporter.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.